2025 Guidelines for the Evaluation and Management of Adults With Congenital Heart Disease
December 19, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Depo-SubQ Provera 104, DepoProvera, MPA, Provera
Synonyms :
medroxyprogesterone
Class :
Progestins; 17alpha-hydroxyprogesterone derivatives
Brand Name :
Depo-SubQ Provera 104, DepoProvera, MPA, Provera
Synonyms :
medroxyprogesterone
Class :
Progestins; 17alpha-hydroxyprogesterone derivatives
Dosage Forms & Strengths
Tablet
2.5mg
5mg
10mg
Intramuscular Suspension
150mg/ml
400mg/ml
Prefilled Suspension for Syringe
104mg/0.65 ml
Indicated for Metastatic Endometrial Carcinoma
Depo-Provera is only indicated for relieving the symptoms of recurrent, metastatic, or inoperable endometrial carcinoma
Initially 400-1000 mg intramuscularly each week
Indicated for Metastatic Renal Carcinoma
Depo-Provera is only indicated for relieving the symptoms of recurrent, metastatic, or inoperable renal carcinoma
Initially 400-1000 mg intramuscularly each week
5-10 mg orally each day for 5-10 days
Start over the therapy at anytime
Provera is only indicated for secondary amenorrhea caused due to imbalance of hormones
These when occurring due to the absence of organic pathologies like uterine cancer or fibroids
3-7 days later, the discontinuation of medroxyprogesterone
Dosage Forms & Strengths
Tablet
2.5mg
5mg
10mg
Intramuscular Suspension
150mg/ml
400mg/ml
Prefilled Suspension for Syringe
104mg/0.65 ml
Refer to the adult dosing
Not required for contraception
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may decrease the diagnostic effect when combined with metyrapone
etonogestrel/ethinyl estradiol
may diminish the serum concentration of each other when combined
may decrease the therapeutic effect of each other when combined
triamcinolone acetonide/nystatin
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
methenamine/sodium salicylate/benzoic acid
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may decrease the therapeutic effect of Antifungal Agents when combined
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inhibitors: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
aprepitant: they may diminish the serum concentration of hormonal contraceptives
cladribine: they may diminish the serum concentration of hormonal contraceptives
fosaprepitant: they may diminish the serum concentration of hormonal contraceptives
octreotide: they may diminish the serum concentration of hormonal contraceptives
ixazomib: they may diminish the serum concentration of hormonal contraceptives
topiramate: they may diminish the serum concentration of hormonal contraceptives
exemestane: they may diminish the serum concentration of hormonal contraceptives
anastrozole: they may diminish the serum concentration of hormonal contraceptives
ulipristal: they may decrease the therapeutic effect of progestins
May lead to a reduction in the concentration serum of Hormonal Contraceptives
Might lead to a reduction in the concentration serum of Hormonal Contraceptives
Might lead to a reduction in the concentration serum of Hormonal Contraceptives
Hormonal Contraceptives increase the effect of thrombogenesis of tranexamic acid
Could potentially reduce the concentration serum of hormonal contraceptives
fezolinetant: they may diminish the serum concentration of hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may enhance the serum concentration when combined with hormonal contraceptives
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
medroxyprogesterone may intensify pegvaliase harmful or hazardous effects
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with Progestins
It may enhance the risk of adverse effects when combined with progesterone derivatives
It may enhance the risk of adverse effects when combined with progesterone derivatives
It may enhance the risk of adverse effects when combined with progesterone derivatives
progestins could potentially intensify the Harmful/toxic effects of chlorprothixene
could potentially lead to a reduction in the concentration serum of Hormonal Contraceptives
The concentration serum of flibanserin may be intensified by hormonal contraceptive
The thrombogenic action of thalidomide may be increased by hormonal contraceptives
Hormonal contraceptives have the potential to elevate the concentration serum of voriconazole
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
It may enhance the risk of adverse reactions when combined with Ergot alkaloids
tovorafenib cannot be taken with hormonal contraceptives
could lead to a reduction in the concentration serum of Hormonal Contraceptives
The thrombogenic effect of carfilzomib might be intensified using hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
mycophenolate could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Actions and Spectrum:
The actions of medroxyprogesterone include:
The spectrum of medroxyprogesterone includes a range of doses and formulations which can be used for different purposes. Some common formulations include:
medroxyprogesterone tablets: Available in different doses, these tablets can be used for contraception, hormone replacement therapy, and to treat abnormal uterine bleeding.
Frequency Defined
>10%
Dysfunctional uterine bleeding
<1%
Breast lump
Anemia
Drug hypersensitivity
Weight decreased
Fluid retention
Facial palsy
Syncope
Paresthesia
Somnolence
Tachycardia
Hot flushes
Asthma
Dyspnea
Diarrhea
Abdominal distension
Urticaria
Pruritus
Dry skin
Dysmenorrhea
Galactorrhea
Dyspareunia
Chest pain
Frequency not Defined
Breakthrough bleeding
Spotting
Erectile dysfunction
Changes in menstrual flow
Amenorrhea
Headache
Dizziness
Somnolence
Convulsions
Mental depression
Insomnia
Nervousness
Pyrexia
Fatigue
Euphoria
Edema
Malaise
Black Box Warning:
The over usage of medroxyprogesterone causes reduced bone mineral density, cardiovascular risks, breast cancers, and risk of dementia.
Contraindication/Caution:
medroxyprogesterone is a synthetic form of progesterone hormone used for various medical conditions. It has some contraindications and cautions that need to be considered before using it. Here are some of them:
Pregnancy consideration:
Not recommended
Breastfeeding warnings:
Lactating mothers should not breastfeed during the therapy
Pregnancy category:
Pharmacology:
medroxyprogesterone acts by binding to progesterone receptors in the uterus, ovaries, and other reproductive organs. It inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by the pituitary gland, which prevents ovulation.
Pharmacodynamics:
medroxyprogesterone is a synthetic progestin that has pharmacodynamic properties like those of natural progesterone. It exerts its pharmacological effects by binding to progesterone receptors, which are present in the reproductive organs, breast, pituitary gland, and hypothalamus.
medroxyprogesterone inhibits the secretion of gonadotropin-releasing hormone (GnRH) from the hypothalamus, which in turn inhibits the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary gland. This leads to a decrease in ovarian function and prevents ovulation.
In addition to its contraceptive effects, medroxyprogesterone has several therapeutic uses. For example, it is used to treat endometriosis, uterine fibroids, and abnormal uterine bleeding. medroxyprogesterone can reduce the proliferation of endometrial tissue and decrease the size and symptoms of uterine fibroids. It can also regulate menstrual bleeding and reduce the risk of endometrial hyperplasia.
medroxyprogesterone can also have some adverse effects. Common side effects include irregular menstrual bleeding, headaches, bloating, and breast tenderness. Rare but serious adverse effects include blood clots, stroke, heart attack, and breast cancer. medroxyprogesterone may also interact with other drugs, such as anticonvulsants and HIV medications, leading to decreased efficacy or increased toxicity.
Pharmacokinetics:
Absorption
Peak plasma concentration for a single dose is 1.01 ng/mL and 0.805 ng/mL for 2.5-mg doses.
For multiple oral doses, 0.71 ng/mL
Distribution
Protein-bound is 90%
The volume of distribution is 78,024 L for 2 x 10-mg doses and 40,654 ng/mL for a 10-mg dose.
Metabolism
Extensive metabolism takes place in the liver through hydroxylation via subsequent conjugation.
Elimination and Excretion
The half-life is 12.1 hours
The drug is excreted in urine
Administration:
medroxyprogesterone is a synthetic form of progesterone, a hormone that plays an essential role in the female reproductive system. It is commonly used for several medical conditions, including irregular menstrual periods, endometriosis, and abnormal uterine bleeding.
The administration of medroxyprogesterone may vary depending on the medical condition being treated, as well as the patient’s age and overall health. It is typically administered as an injection into the muscle/under skin/orally as a tablet.
Patient information leaflet
Generic Name: medroxyprogesterone
Pronounced: med-ROX-ee-proe-JES-ter-one
Why do we use medroxyprogesterone?
medroxyprogesterone is a synthetic form of the hormone progesterone, which plays a vital role in the female reproductive system. It is used to treat a variety of medical conditions, including:
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
